News HDL Therapeutics eyes public listing in $480m SPAC deal US medical device company HDL Therapeutics is aiming to list on the Nasdaq via a merger with Swiftmerge Acquisition, a special purpose acquisition company (SPAC).
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.